Figure 8.

Proposed strategies to develop new cancer therapeutics by targeting biomolecular condensates. As illustrated in main text and listed in Table 2, the strategies include: A) Targeting intrinsically disordered regions (IDRs) that drive condensates formation; B) decondensation or recondensation dependent on the function of condensation, for example, by directly regulating the physiochemical properties of condensates; C) drug partitioning to concentrate drugs in condensates and increase treatment efficiency; and D) disrupting the modifications of condensate components, such as PTMs‐related enzymes or PTMs themselves, to affect condensates formation.